A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy

A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy

Abstract Background CD19 chimeric antigen receptor (CAR) therapy has achieved impressive success in relapsed or refractory (R/R) B-cell malignancies, but relapse due to antigen escape is increasingly appearing reported. As the expression profile of CD22 is similar to that of CD19, CD22 has become a...

Full description

Bibliographic Details
Main Authors: Yu Zhang, Saisai Li, Ying Wang, Yang Lu, Yingxi Xu, Qing Rao, Huijun Wang, Haiyan Xing, Zheng Tian, Kejing Tang, Lulu Lv, Min Wang, Jianxiang Wang
Format: Article
Language:English
Published: BMC 2022-03-01
Series:Experimental Hematology & Oncology
Subjects:
CD22
HIB22
CD19
CAR-T
Sequential therapy
B-ALL
Online Access:https://doi.org/10.1186/s40164-022-00270-5

Internet

https://doi.org/10.1186/s40164-022-00270-5

Similar Items